| EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update JS Smolen, RBM Landewé, JWJ Bijlsma, GR Burmester, M Dougados, ... Annals of the rheumatic diseases 79 (6), 685-699, 2020 | 2589 | 2020 |
| Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results … ML Hetland, IJ Christensen, U Tarp, L Dreyer, A Hansen, IT Hansen, ... Arthritis & Rheumatism: Official Journal of the American College of …, 2010 | 660 | 2010 |
| MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA) ML Hetland, B Ejbjerg, K Hørslev-Petersen, S Jacobsen, A Vestergaard, ... Annals of the rheumatic diseases 68 (3), 384-390, 2009 | 490 | 2009 |
| Inequities in access to biologic and synthetic DMARDs across 46 European countries P Putrik, S Ramiro, TK Kvien, T Sokka, M Pavlova, T Uhlig, A Boonen, ... Annals of the rheumatic diseases 73 (1), 198-206, 2014 | 378 | 2014 |
| Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has … K Chatzidionysiou, E Lie, E Nasonov, G Lukina, ML Hetland, U Tarp, ... Annals of the rheumatic diseases 70 (9), 1575-1580, 2011 | 310 | 2011 |
| EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis HW van Steenbergen, D Aletaha, LJJ Beaart-van de Voorde, E Brouwer, ... Annals of the rheumatic diseases 76 (3), 491-496, 2017 | 308 | 2017 |
| Health-related quality of life: validity, reliability, and responsiveness of SF-36, EQ-15D, EQ-5D, RAQoL, and HAQ in patients with rheumatoid arthritis L Linde, J Sørensen, M Østergaard, K Hørslev-Petersen, ML Hetland The Journal of rheumatology 35 (8), 1528-1537, 2008 | 299 | 2008 |
| Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance … B Glintborg, M Østergaard, NS Krogh, L Dreyer, HL Kristensen, ... Annals of the rheumatic diseases 69 (11), 2002-2008, 2010 | 290 | 2010 |
| Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti–tumor necrosis factor α therapy: results from the … B Glintborg, M Østergaard, L Dreyer, NS Krogh, U Tarp, MS Hansen, ... Arthritis & Rheumatism 63 (2), 382-390, 2011 | 286 | 2011 |
| Low bone mass and high bone turnover in male long distance runners ML Hetland, J Haarbo, C Christiansen The Journal of Clinical Endocrinology & Metabolism 77 (3), 770-775, 1993 | 268 | 1993 |
| QUEST-RA: quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries T Sokka, H Kautiainen, S Toloza, H Mäkinen, SMM Verstappen, ... Annals of the rheumatic diseases 66 (11), 1491-1496, 2007 | 264 | 2007 |
| A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry B Glintborg, IJ Sørensen, AG Loft, H Lindegaard, A Linauskas, ... Annals of the rheumatic diseases 76 (8), 1426-1431, 2017 | 247 | 2017 |
| Radiographic progression and remission rates in early rheumatoid arthritis–MRI bone oedema and anti-CCP predicted radiographic progression in the 5-year extension of the double … ML Hetland, K Stengaard-Pedersen, P Junker, M Østergaard, BJ Ejbjerg, ... Annals of the rheumatic diseases 69 (10), 1789-1795, 2010 | 240 | 2010 |
| Combination treatment with methotrexate, cyclosporine, and intraarticular betamethasone compared with methotrexate and intraarticular betamethasone in early active rheumatoid … ML Hetland, K Stengaard‐Pedersen, P Junker, T Lottenburger, ... Arthritis & Rheumatism: Official Journal of the American College of …, 2006 | 228 | 2006 |
| Silica exposure among male current smokers is associated with a high risk of developing ACPA-positive rheumatoid arthritis P Stolt, A Yahya, C Bengtsson, H Källberg, J Rönnelid, I Lundberg, ... Annals of the rheumatic diseases 69 (6), 1072-1076, 2010 | 220 | 2010 |
| Remission and rheumatoid arthritis: data on patients receiving usual care in twenty‐four countries T Sokka, ML Hetland, H Mäkinen, H Kautiainen, K Hørslev‐Petersen, ... Arthritis & Rheumatism 58 (9), 2642-2651, 2008 | 219 | 2008 |
| Disparities in rheumatoid arthritis disease activity according to gross domestic product in 25 countries in the QUEST–RA database T Sokka, H Kautiainen, T Pincus, S Toloza, GRC Pinheiro, J Lazovskis, ... Annals of the rheumatic diseases 68 (11), 1666-1672, 2009 | 217 | 2009 |
| No overall progression and occasional repair of erosions despite persistent inflammation in adalimumab-treated rheumatoid arthritis patients: results from a longitudinal … UM Døhn, B Ejbjerg, A Boonen, ML Hetland, MS Hansen, LS Knudsen, ... Annals of the rheumatic diseases 70 (2), 252-258, 2011 | 205 | 2011 |
| Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the … B Glintborg, M Østergaard, NS Krogh, MD Andersen, U Tarp, AG Loft, ... Arthritis & Rheumatism 65 (5), 1213-1223, 2013 | 203 | 2013 |
| Incidences of overall and site specific cancers in TNFα inhibitor treated patients with rheumatoid arthritis and other arthritides–a follow-up study from the DANBIO Registry L Dreyer, L Mellemkjær, AR Andersen, P Bennett, UE Poulsen, ... Annals of the rheumatic diseases 72 (1), 79-82, 2013 | 194 | 2013 |
